Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: A concise update

Nuclear Medicine and Biology

Volumn 30, Issue 8, 2003, Pages 861-868

  Smith, C J ^a,b   Volkert, W A ^a,b   Hoffman, T J ^a,b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; GASTRIN RELEASING PEPTIDE; NEUROMEDIN B; PEPTIDE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RECEPTOR PROTEIN; TECHNETIUM 99M;

BINDING AFFINITY; BREAST TUMOR; CHELATION; CONFERENCE PAPER; CONJUGATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; FEASIBILITY STUDY; IC 50; ISOTOPE LABELING; LUNG SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; PROTEIN EXPRESSION; SYSTEM ANALYSIS;

EID: 0347991822     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00116-1     Document Type: Conference Paper

References (72)

1. Kwekkeboom D., Krenning E.P., de Jong M. Peptide Receptor Imaging and Therapy. J Nucl Med. 41:(10):2000;1704-1713.
2. Krenning E.P., de Jong M. Therapeutic use of radiolabelled peptides. Ann Oncol. 11:(3):2000;267-271.
3. Blum J.E., Handmaker H. Small peptide radiopharmaceuticals in the imaging of acute thrombus. Curr Pharm Des. 8:(20):2002;1815-1826.
4. Blum J., Handmaker H., Rinne N.A. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Des. 8:(20):2002;1827-1836.
5. Behr T.M., Gotthardt M., Barth A., Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med. 45:(2):2001;189-200.
6. Signore A., Annovazzi A., Chianelli M., Corsetti F., Van De Wiele C., Waterhourse R.N., et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med. 28:(10):2001;1555-1565.
7. Okarvi S.M. Recent progress in fluoring-18 labeled peptide radiopharmaceuticals. Eur J Nucl Med. 28:(7):2001;929-938.
8. Liu S., Edwards D.S. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem Rev. 99:(9):1999;2235-2268.
9. Blok D., Feitsma R.I.J., Vermeij P., Pauwels E.J.K. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med. 26:(11):1999;1511- 1519.
10. Boerman O.C., Oyen W.J.G., Corstens F.H.M. Radio-Labeled Receptor-Binding Peptides A New Class of Radiopharmaceuticals . Sem Nucl Med. 30:(3):2000;195-208.
11. Goodwin D.A., Meares C.F. Pretargeted Peptide Imaging and Therapy. Cancer Biother Radiopharm. 14:1999;145-152.
12. 1]-[123I-Tyr- 3-]-octreotide the Rotterdam experience with more than 1000 patients . Eur J Nucl Med. 20:1993;716-731.
13. Spindel E.R., Giladi E., Brehm P., Goodman R.H., Seferson T.P. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol. 4:1990;1956-1963.
14. Battey J.F., Way J.M., Corjay M.H., Kusano K., Harkins R., Wu J.M., et al. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA. 88:(2):1991;395-399.
15. Von Schrenck T., Heinz-Erian P., Moran T., Mantey S.A., Gardner J.D., Jensen R.T. Neuromedin B receptor in oesophagus Evidence for subtypes of bombesin receptors . Am J Physiol. 256:1989;G747-G758.
16. Wada E., Way J., Shapira H., Kusano K., Lebacq-Verheyden A.M., Coy D., et al. cDNA cloning, characterization, and brain region-specific expression of a neuromedin B-perferring bombesin receptor. Neuron. 6:(3):1991;421-430.
17. 13]bombesin distinct from the receptor for gastrin-releasing peptide Identification of a fourth bombesin receptor subtype (BB4) . Proc Natl Acad Sci USA. 92:1995;6205-6209.
18. Fathi Z., Corjav M.H., Shapira H., Wada E., Benya R., Jensen R., et al. BRS-3 Novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells . J Biol Chem. 268:(8):1993;5979-5984.
19. Pradhan T.K., Katsuno T., Taylor J.E., Kim S.H., Ryan R.R., Mantey S.A., et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharm. 343:1998;275-287.
20. Anastasi A., Erspamer V., Nucci M. Isolation and amino acid sequences of alytesin and bombesin, two analogous active tetradecapeptides from the skin of European discoglossid Frogs. Arch Biochem Biophys. 148:(2):1972;443-446.
21. McDonald T.J., Jornvall H., Nilsson G., Vag Bloom S.R., Mutt V. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Comm. 90:(1):1979;227-233.
22. Sun B., Halmos G., Schally A.V., Wang X., Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and nRNA for three receptor subtypes in human prostate cancers. Prostate. 42:2000;295-303.
23. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in human prostate relation to neoplastic transformation . Cancer Res. 59:1999;1152-1159.
24. Gugger M., Reubi J.C. GRP receptors in nonneoplastic and neoplastic human breast. Am J Pathol. 155:1999;2067-2076.
25. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A., et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 316:1985;823-826.
26. Moody T.W., Bertness V., Carney D.N. Bombesin-like peptides and receptors in human tumor cell lines. Peptides. 4:1983;683-686.
27. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate relation to neoplastic transformation . Cancer Res. 59:1999;1152-1159.
28. Pinski J., Halmos G., Yano T., Szepeshazi K., Qin Y., Ertl T., et al. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer. 57:1994;574-580.
29. Sun B., Schally A.V., Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept. 90:2000;77-84.
30. Aprikian A.G., Han K., Chevalier S., Bazinet M., Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol. 16:1996;297-306.
31. Burns D.M., Walker B., Gray J., Nelson J. Breast cancer cell-associated endopeptidase EC 24.11 modulates proliferative response to bombesin. Br J Cancer. 79:1999;214-220.
32. Giacchetti S., Gauville C., de Cremoux P., Berti L., Berthon P., Abita J.P., et al. Characterization, in some human breast cancer cell lines, of gastrin- releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer. 46:1990;293-298.
33. Halmos G., Wittliff J.L., Schally A.V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 55:1995;280-287.
34. Nelson J., Donnelly M., Walker B., Gray J., Shaw C., Murphy R.F. Bombesin stimulates proliferation of human breast cancer cells in culture. Br J Cancer. 63:1991;933-936.
35. Yano T., Pinski J., Groot K., Schally A.V. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 52:1992;4545-4547.
36. Yano T., Pinski J., Szepeshazi K., Halmos G., Radulovic S., Groot K., et al. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC- 3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 73:1994;1229-1238.
37. Xiao D., Wang J., Hampton L.L., Weber H.C. The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene. 264:2001;95-103.
38. Jurisson S., Berning D., Jia W., Ma D. Coordination compounds in nuclear medicine. Chem Rev. 93:1993;1137-1156.
39. 2] Syntheses, Radiolabeling and In Vitro/In Vivo GRP Receptor Targeting Studies . AntiCancer Res. 23:2003;63-70.
40. Baidoo K.E., Lin K.-S., Zhan Y., Finley P., Scheffel U., Wagner H.N. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconj Chem. 9:1998;218-225.
41. 188Re of Peptide Conjugates Containing a Dithia-bisphosphine Chelating Agent. Bioconj Chem. 12:2001;354-363.
42. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconj Chem. 10:1999;254-260.
43. 2 An in Vitro/in Vivo Structure-Activity Relationship Study Where X = 0, 3, 5, 8, and 11-Carbon Tethering Moteties . Bioconj Chem. 14:2003;93-102.
44. Van de Wiele C., Dumont F., Broecke R.V., Oosterlinck W., Cocquyt V., Serreyn R., et al. Technetium-99m RP525, a GRP analogue for visualization of GRP receptor-expressing malignancies A feasible study . Eur J Nucl Med. 27:2000;1694-1699.
45. 99mTc-RP-527, a gastrin releasing peptide(GRP) analogue for visualization of GRP receptor expressing malignancies A feasibility study . Nucl Med Commun. 21:2000.
46. Nock B., Nikolopoulou A., Chiotellis E., Loudos G., Maintas D., Reubi J.C., et al. [99mTc] Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med. 30:(2):2003;247-258.
47. 3]2-Synthesis, Characterization, and Structures of Rhenium(I) Tricarbonyl Complexes with Thiourea and Thiourea Derivatives. Inorg Chim Acta. 248:1996;193-202.
48. 3 Moieties to Biologically Active Molecules. Bioconj Chem. 11:2000;414-424.
49. +-Core. Nucl Med Biol. 26:1999;711-716.
50. 6. Inorg Chem. 37:1998;5306-5312.
51. +. Nicolini M., Ulderico M. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. 1999;27-34 SGE, Italy.
52. + Labels Peptide to an Unprecedented High Specific Activity. A Labelling Study with Amino Acids and Neurotensin. Nicolini M., Ulderico M. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. 1999;507-512 SGE, Italy.
53. 99mTc(I)- Labeled Bombesin Analogue for Imaging of Gastrin Releasing Peptide Receptor-Positive Tumors. Nucl Med Biol. 29:2002;553-560.
54. + and Synthesis of Tailor-Made Bifunctional Ligand Systems . Bioconj Chem. 13:2002;750-756.
55. 3. Cancer Res (In Press) 2003.
56. 2], a New Family of GRP-receptor Targeting Radiopharmaceuticals. Nicolini M., Mazzi U. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. 2002;339-344 SGE Editoriali, Padova, Italy. , 6.
57. Cutler C.S., Smith C.J., Ehrhardt G.L., Tyler T.T., Jurisson S.S., Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm. 15:(6):2000;531-545.
58. 3]-Octreotide The Rotterdam experience with more than 1000 patients . Eur J Nucl Med. 20:1993;716-731.
59. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy . J Med Chem. 42:1999;1341-1347.
60. Smith-Jones P.M., Stolz B., Albert R., Ruser G., Maecke H., Briner U., et al. Synthesis, radiolabeling, and evaluation of DTPA/Octreotide conjugates for radiotherapy. J Labelled Compd Radiopharm. 37:1995;499-501.
61. Stolz B., Smith-Jones P.M., Weckbecker G., Albert R., Knecht H., Haller R., et al. Radiotherapy with Yttrium-90 labeled DOTA-Tyr3-Octreotide in tumor bearing rodents. J Nucl Med. 38:1997;18.
62. Otte A., Mueller-Brand J., Goetze M., Hermann R., Knecht H.R., Maecke H.R. Yttrium-90-DOTA-Octreotide treatment of somatostatin receptor positive tumors. J Nucl Med. 39:1998;70.
63. Anderson C.J., Jones L.A., Bass L.A., Sherman E.L.C., McCarthy D.W., Cutler P.D., et al. Radiotherapy, toxicity, and dosimetry of Copper-64-TETA-Octreotide in tumor-bearing Rats. J Nucl Med. 39:1998;1944-1951.
64. Rogers B.E., Brechbiel M.W., Kirkman R.L., Clarkson M., Buchsbaum D.J. In Vitro binding and internalization of an Indium-111 labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor. Nicolini M., Mazzi U. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. 1999;519-525 SGE Editoriali, Italy.
65. Breeman W.A.P., Hofland L.J., DeJong M., Bernard B.F., Srinivasan A., Kweekeboom D.J., et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 81:1999;658-665.
66. 2 (X = 0, β-Ala, 5-Ava, 8-Aoc, or 11-Aun) analogs as potential radiopharmaceuticals for specific-targeting of gastrin releasing peptide (GRP) receptors expressed on human prostate cancer PC-3 cells. J Nucl Med. 44:2003;823-831.
67. 2 An In Vitro/In Vivo Assessment of the Targeting Ability of this New Radiopharmaceutical for PC-3 Human Prostate Cancer Cells . Nucl Med Biol. 30:2003;101-109.
68. 2 A new gastrin releasing peptide receptor (GRPr) targeting radiopharmaceutical . J Labelled Compd Radiopharm. 44:2001;706-708.
69. 105Rh(III) Complexes with macrocycles. J Labelled Compd Radiopharm. 37:1995;426-428.
70. 105Rh labeled bombesin analogues Enhancement of GRP receptor binding affinity utilizing aliphatic carbon chain linkers . J Labelled Compd Radiopharm. 40:1997;490-493.
71. Ning L. Synthesis and Characterization of 105Rh-Labeled Thiamacrocycles for use to Formulate Peptide Receptor Agents. [dissertation]:1996;Univ. Missouri, Columbia.
72. Rogers B.E., Brechbiel M.W., Kirkman R.L., Clarkson M., Buchsbaum D.J. In Vitro Binding and Internalization of Indium-111 Labeled Bombesin Derivative to Cells Expressing the Gastrin Releasing Peptide Receptor. Nicolini M., Mazzi U. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. 1999;SGE Editoriali, Padova, Italy.